Pens, storage, and missed doses
Compounded Semaglutide Storage: Vials, BUDs, Warning Signs
How to store compounded semaglutide and tirzepatide vials, what a beyond-use date means, and the signs that a vial may be compromised and should not be used.
Last reviewed
The Vital angle
Vital lets you mark a dose as compounded and save the vial's lot number, an expiration date, and notes about storage or shipping with each log. Your dose history shows when you first used a vial, which helps you track the 28-day limit, and dose reminders keep the schedule on track.
Why compounded semaglutide storage is different
Compounded semaglutide storage has no single official rule. Brand pens like Ozempic® and Wegovy® come with an FDA-approved label that sets exact storage times. A compounded vial does not. The FDA says compounded drugs are not FDA-approved and that it does not check their safety, quality, or effectiveness before they are sold. The storage rules come from the pharmacy that made the vial.
That puts more of the work on you. You must read the pharmacy label, track the dates yourself, and check the vial each time you use it. The same applies to compounded tirzepatide. For background on how compounded products differ from brand products, see compounded vs brand semaglutide.
Read the pharmacy label first
Your vial label and the pharmacy handout are the primary instructions. Before the first dose, find these items:
- The drug and its concentration, for example in mg per mL. Concentrations vary between pharmacies, and one pharmacy can make several.
- The storage temperature. Follow the temperature on your label, because it can differ between pharmacies.
- The beyond-use date (BUD). This is the last date the vial can be used.
- Any in-use limit, such as "discard 28 days after first use."
- The pharmacy name, address, and phone number.
If any of these are missing, or the label has spelling errors or a wrong address, call the pharmacy before you use the vial. The FDA lists label errors and medicine that looks different or arrives damaged as warning signs.
Beyond-use date versus 28 days after opening
A compounded vial has two clocks, and both apply.
The beyond-use date is set by the pharmacy when it makes the vial. It is based on how the drug was made and tested. It works like an expiration date for a compounded product.
The in-use time starts the first time a needle goes through the rubber stopper. The CDC says an opened multi-dose vial should be dated and thrown away within 28 days, unless the manufacturer gives another date. That follows the USP standard for sterile compounding, Chapter 797. The FDA goes further for compounded GLP-1 vials: it says to discard a vial 28 days after first use, even if medicine is left and even if the compounder says it lasts longer. The reason is that the risk of contamination rises each time the stopper is punctured.
Use whichever date comes first. A practical habit:
- Write the date of first use on the vial label or carton with a marker.
- Add 28 days and write that date too.
- Compare it with the BUD printed on the label, and circle the earlier one.
How to store a compounded vial day to day
General handling rules for an injectable vial, unless your label says otherwise:
- Keep the vial at the temperature on the label. For a refrigerated vial, use the main body of the fridge, not the door or the back wall where items can freeze.
- Do not freeze the vial unless the label says to. Do not use a vial that froze when it was not meant to.
- Keep it in its box or out of direct light.
- Keep the stopper clean. Wipe it with an alcohol swab before each draw and let it dry.
- Use a new sterile needle and syringe every time. The CDC says never to leave a needle in the stopper for later use.
- Keep the vial away from heat sources and out of a parked car.
If your vial was left out, the general guidance in GLP-1 left out of the fridge applies, but brand-pen room-temperature times do not transfer to compounded vials. Call your pharmacy with the time and temperature.
Warm shipments and ice packs
Many compounded vials arrive by mail. The FDA says it has received complaints of compounded GLP-1 drugs that arrived warm or with too few ice packs. It advises patients not to use an injectable GLP-1 drug that arrives warm or without enough cold packing, because heat can affect quality.
When a package arrives:
- Open it the same day and check that the cold packs are still cold.
- Look at the vial for the warning signs in the next section.
- If the package was warm, or the packs were fully melted, take photos and call the pharmacy before you use the vial.
- Put the vial in the refrigerator right away if it looks fine and the pharmacy confirms.
For trips, the travel guide covers coolers and airport screening.
Signs a vial may be compromised
The CDC says to discard any medication vial when its sterility is compromised or questionable. Do not use the vial, and call the pharmacy, if you see any of these:
- Cloudiness or particles in a liquid that the label describes as clear.
- A color change compared with when you got it.
- A cracked vial, a loose or missing cap, or a damaged stopper.
- A label that does not match your prescription, or no BUD at all.
- A date past the BUD or past 28 days from first use.
- A vial that froze, or one that sat warm for an unknown time.
- A source you are not sure of. The FDA warns against products sold "for research purposes" or "not for human consumption." These are not compounded for patients.
If you have injected from a vial and feel unwell, do not wait to see if the problem is the vial. Call your prescriber.
Measuring the dose from a vial
Storage and dosing errors often go together. The FDA has reported adverse events, some needing hospital care, from dosing mistakes with compounded semaglutide. Causes included confusion between milligrams, milliliters, and syringe "units," different concentrations between products, and multiple-dose vials. In some reports, patients drew 50 units on a U-100 syringe when they meant to draw 5. Across the reports, patients took 5 to 20 times the intended dose.
Ask your prescriber or pharmacy to write your dose in both mg and in mL or units for your exact vial, and to name the syringe size to use. If your vial changes, ask again, because a new concentration means a new volume. For more on schedules, see dosing schedules.
The FDA lists these overdose symptoms: nausea, vomiting, stomach pain, fainting, headache, migraine, and dehydration. Pancreatitis and gallstones were also reported. Severe stomach pain that will not go away needs care right away. If you think you took too much, call your prescriber or Poison Help at 1-800-222-1222, or go to an emergency room.
Check the pharmacy and report problems
The FDA advises getting a prescription from a licensed prescriber and filling it at a state-licensed pharmacy. A 503A pharmacy is overseen mainly by its state board of pharmacy. A 503B outsourcing facility registers with the FDA and must follow manufacturing quality rules. You can ask your pharmacy which one it is.
If a vial looks wrong or you have a side effect you think is linked to it, report it to the FDA MedWatch program and tell the pharmacy. Keep the vial, the box, and the label until the pharmacy tells you what to do.
Ozempic® and Wegovy® are trademarks of Novo Nordisk A/S. Vital is independent and not affiliated with these companies.
Things to watch
Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.
Using a multi-dose vial past 28 days after first use
The FDA says to discard a compounded GLP-1 vial 28 days after first use, even if medicine is left and even if the compounder says it lasts longer, because contamination risk rises with each puncture.
Using a vial that arrived warm
The FDA has received complaints of compounded GLP-1 drugs that arrived warm or with too few ice packs, and advises not to use an injectable GLP-1 that arrives without enough refrigeration.
Cloudiness, particles, or a color change
The CDC says to discard any medication vial when sterility is compromised or questionable. A visible change in the liquid is a reason to call the pharmacy before use.
Mixing up mg, mL, and syringe units
The FDA reported hospitalizations linked to dosing errors with compounded semaglutide, including patients who drew 50 units instead of 5 on a U-100 syringe.
Reusing a needle or leaving one in the stopper
The CDC says not to leave a needle in a vial stopper for later use. A new sterile needle and syringe for each dose lowers the risk of contaminating the vial.
Products labeled for research use
The FDA warns about semaglutide and tirzepatide sold "for research purposes" or "not for human consumption." These are not compounded for patients and have no patient storage instructions.
Frequently asked questions
Follow the storage temperature on the pharmacy label, because compounded vials have no FDA-approved label. Keep the vial out of light, do not freeze it unless the label says to, and keep it away from heat.
The FDA says to discard a compounded GLP-1 multi-dose vial 28 days after first use, even if medicine is left. If the beyond-use date on the label comes sooner, use that date instead.
It is the last date the pharmacy says the vial can be used, based on how it was made and tested. It is separate from the 28-day limit that starts when a needle first goes through the stopper. Use whichever comes first.
The FDA advises against using an injectable GLP-1 that arrives warm or without enough refrigeration. Take photos of the package and call the pharmacy before you use it.
Do not use it, and call the pharmacy, if the liquid is cloudy, has particles, or changed color, if the vial is cracked or the stopper is damaged, if it froze, or if it is past the beyond-use date or 28 days from first use.
The same principles apply: follow the pharmacy label, respect the beyond-use date, and discard a multi-dose vial 28 days after first use. Ask your pharmacy if your label is unclear.
Sources
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · U.S. Food and Drug Administration
- FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products · U.S. Food and Drug Administration
- Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration
- Preventing Unsafe Injection Practices · Centers for Disease Control and Prevention
- Safely Using Sharps (Needles and Syringes) at Home, at Work and on Travel · U.S. Food and Drug Administration
This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.
Track every shot, every change
Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.
More from the Library
Ozempic Left Out of the Fridge? Room-Temperature Limits by Brand
Each GLP-1 label gives its own room-temperature limit, and every one says not to use a pen that froze. Here is what the Ozempic, Wegovy, Mounjaro, and Zepbound labels allow, and what to do next.
Can't Find Your Wegovy or Zepbound Dose? Options to Discuss
The national GLP-1 shortages are over, but a local pharmacy can still run out of one strength. Here are the options to raise with your pharmacist and prescriber, and the records that make each call shorter.
How to Read Insulin Syringe Units: Tick Marks on 0.3, 0.5, and 1 mL Barrels
How to read insulin syringe units on a U-100 barrel, what each line means on a 30, 50, and 100 unit syringe, how units convert to mL, and the misreads that cause dosing errors.
Peptide Reconstitution Calculator: BAC Water Ratio and Concentration Math
How peptide reconstitution works, how a BAC water ratio sets the concentration in mg per mL, the sterile steps for mixing a vial, and how to store it after mixing.